Shots: The P-III SUNRISE 2 study involves assessing of Lemborexant (5mg,10mg) vs PBO in 949 patients with insomnia disorder, characterized by difficulty in falling asleep/staying asleep aged 18 to 88yrs. P-III SUNRISE 2 study results: reductions in sleep onset latency (sSOL) (-21.81, -28.21 vs -11.43 min); improvement in sSE (14.19%, 14.31% vs 9.64%); reduction in […]Read More
